{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:45Z","timestamp":1791465105006,"version":"4.3.4"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences Europe Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most invasive fungal infections are opportunistic in nature but the epidemiology is constantly changing, with new risk groups being identified. Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections. Factors to be considered when choosing antifungal treatment include the emergence of rarer fungal pathogens, the risk of resistance to azoles and echinocandins and the possibility of drug\u2013drug interactions. Liposomal amphotericin B has retained its place in the therapeutic armamentarium based on its clinical profile: a broad spectrum of antifungal activity with a low risk of resistance, predictable pharmacokinetics with a rapid accumulation at the infection site (including biofilms), a low potential for drug\u2013drug interactions and a low risk of acute and chronic treatment-limiting toxicities versus other formulations of amphotericin B. It is a suitable choice for the first-line empirical or pre-emptive treatment of suspected fungal infections in neutropenic haematology patients and is an excellent alternative for patients with documented fungal disease who can no longer tolerate or continue their first-line azole or echinocandin therapy, both in the haematology setting and in the ICU. Moreover, it is the first-line drug of choice for the treatment of invasive mucormycosis. Finally, liposomal amphotericin B is one of the few antifungal agents approved for use in children of all ages over 1\u2005month and is included in paediatric-specific guidelines for the management of fungal disease.<\/jats:p>","DOI":"10.1093\/jac\/dkac352","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:17:43Z","timestamp":1669378663000},"page":"ii11-ii20","source":"Crossref","is-referenced-by-count":55,"title":["Liposomal amphotericin B\u2014the present"],"prefix":"10.1093","volume":"77","author":[{"given":"J","family":"Maertens","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Gasthuisberg, KU Leuven , Leuven , Belgium"},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Pagano","sequence":"additional","affiliation":[{"name":"Sezione di Ematologia, Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS\u2014Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Azoulay","sequence":"additional","affiliation":[{"name":"M\u00e9decine Intensive et R\u00e9animation, H\u00f4pital Saint-Louis, APHP, University of Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Warris","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"},{"name":"Great Ormond Street Hospital, Paediatric Infectious Diseases Unit , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2022112510090321100_dkac352-B1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2022112510090321100_dkac352-B2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"2022112510090321100_dkac352-B3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B4","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug-drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2022112510090321100_dkac352-B5","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J Infect Dis"},{"key":"2022112510090321100_dkac352-B6","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022112510090321100_dkac352-B7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022112510090321100_dkac352-B8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2022112510090321100_dkac352-B9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2022112510090321100_dkac352-B10","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022112510090321100_dkac352-B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B12","author":"Electronic Medicines Compendium"},{"key":"2022112510090321100_dkac352-B13","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2022112510090321100_dkac352-B14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2013Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2014.113399","article-title":"Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)","volume":"100","author":"Caira","year":"2015","journal-title":"Haematologica"},{"key":"2022112510090321100_dkac352-B16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"2022112510090321100_dkac352-B17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1399-3062.1999.010406.x","article-title":"Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability","volume":"1","author":"Tiphine","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"2022112510090321100_dkac352-B18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2022112510090321100_dkac352-B19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2022112510090321100_dkac352-B20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2022112510090321100_dkac352-B21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022112510090321100_dkac352-B22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2022112510090321100_dkac352-B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u20132","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2022112510090321100_dkac352-B24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2022112510090321100_dkac352-B25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2022112510090321100_dkac352-B26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/myc.12161","article-title":"Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study","volume":"57","author":"Candoni","year":"2014","journal-title":"Mycoses"},{"key":"2022112510090321100_dkac352-B27","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2022112510090321100_dkac352-B28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"2022112510090321100_dkac352-B29","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10\u2005mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022112510090321100_dkac352-B30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022112510090321100_dkac352-B31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112510090321100_dkac352-B32","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"2022112510090321100_dkac352-B33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2008.355","article-title":"A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT","volume":"43","author":"Hebart","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2022112510090321100_dkac352-B35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"2022112510090321100_dkac352-B36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"2022112510090321100_dkac352-B37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"2022112510090321100_dkac352-B38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14787210.2018.1496329","article-title":"Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons","volume":"16","author":"Busca","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022112510090321100_dkac352-B39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2022112510090321100_dkac352-B40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ejh.13387","article-title":"Ibrutinib as initial therapy in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"104","author":"Molica","year":"2020","journal-title":"Eur J Haematol"},{"key":"2022112510090321100_dkac352-B41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"key":"2022112510090321100_dkac352-B42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccell.2017.05.004","article-title":"Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis","volume":"31","author":"Grommes","year":"2017","journal-title":"Cancer Cell"},{"key":"2022112510090321100_dkac352-B44","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B45","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1378\/chest.08-1741","article-title":"ARDS: a clinicopathological confrontation","volume":"135","author":"de Hemptinne","year":"2009","journal-title":"Chest"},{"key":"2022112510090321100_dkac352-B46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B47","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B48","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"2022112510090321100_dkac352-B49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"Kett","year":"2011","journal-title":"Crit Care Med"},{"key":"2022112510090321100_dkac352-B50","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2022112510090321100_dkac352-B51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/mmy\/myaa036","article-title":"Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: a study by the Fungal PCR Initiative and the Modimucor study group","volume":"59","author":"Rocchi","year":"2021","journal-title":"Med Mycol"},{"key":"2022112510090321100_dkac352-B52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13054-020-2766-1","article-title":"Risk factors for candidemia: a prospective matched case-control study","volume":"24","author":"Poissy","year":"2020","journal-title":"Crit Care"},{"key":"2022112510090321100_dkac352-B53","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit","year":"2016","journal-title":"JAMA"},{"key":"2022112510090321100_dkac352-B54","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/CCM.0b013e318236f297","article-title":"Systemic antifungal therapy in critically ill patients without invasive fungal infection","volume":"40","author":"Azoulay","year":"2012","journal-title":"Crit Care Med"},{"key":"2022112510090321100_dkac352-B55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jinf.2016.12.016","article-title":"Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: a post-hoc causal inference model using the AmarCAND2 study","volume":"74","author":"Bailly","year":"2017","journal-title":"J Infect"},{"key":"2022112510090321100_dkac352-B56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13613-015-0103-7","article-title":"Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study","volume":"6","author":"Leroy","year":"2016","journal-title":"Ann Intensive Care"},{"key":"2022112510090321100_dkac352-B57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2022112510090321100_dkac352-B58","first-page":"11","article-title":"Epidemiology and antifungal susceptibility of Candida species causing blood stream infections: an Eastern India perspective","volume":"69","author":"Chakraborty","year":"2021","journal-title":"J Assoc Physicians India"},{"key":"2022112510090321100_dkac352-B59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/jof3020024","article-title":"Revisiting species distribution and antifungal susceptibility of Candida bloodstream isolates from Latin American medical centers","volume":"3","author":"da Matta","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2022112510090321100_dkac352-B60","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based Candidemia Surveillance Program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2022112510090321100_dkac352-B61","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/imj.14612","article-title":"Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases","volume":"49","author":"Ong","year":"2019","journal-title":"Intern Med J"},{"key":"2022112510090321100_dkac352-B62","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s00134-013-3109-3","article-title":"A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts","volume":"39","author":"Bassetti","year":"2013","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B63","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","article-title":"A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijantimicag.2008.07.030","article-title":"Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms","volume":"33","author":"Mukherjee","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 7","key":"2022112510090321100_dkac352-B65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022112510090321100_dkac352-B66","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B67","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3109\/23744235.2015.1028100","article-title":"Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemia","volume":"47","author":"Ng","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"2022112510090321100_dkac352-B68","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022112510090321100_dkac352-B69","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00134-017-4717-0","article-title":"Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B71","doi-asserted-by":"crossref","first-page":"e0252165","DOI":"10.1371\/journal.pone.0252165","article-title":"Candidemia in intensive care units over nine years at a large Italian university hospital: comparison with other wards","volume":"16","author":"Mazzanti","year":"2021","journal-title":"PLoS One"},{"key":"2022112510090321100_dkac352-B72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhin.2009.07.003","article-title":"Invasive pulmonary aspergillosis in intensive care units: is it a real problem?","volume":"74","author":"Bassetti","year":"2010","journal-title":"J Hosp Infect"},{"key":"2022112510090321100_dkac352-B73","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1186\/cc3488","article-title":"Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome","volume":"9","author":"Garnacho-Montero","year":"2005","journal-title":"Crit Care"},{"key":"2022112510090321100_dkac352-B74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/CCM.0b013e318236f64f","article-title":"Clinical diagnoses and autopsy findings: discrepancies in critically ill patients","volume":"40","author":"Tejerina","year":"2012","journal-title":"Crit Care Med"},{"key":"2022112510090321100_dkac352-B75","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/myc.12927","article-title":"Invasive aspergillosis in critically ill patients: an autopsy study","volume":"62","author":"Tejerina","year":"2019","journal-title":"Mycoses"},{"key":"2022112510090321100_dkac352-B76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-016-0156-2","article-title":"Aspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study","volume":"6","author":"Contou","year":"2016","journal-title":"Ann Intensive Care"},{"key":"2022112510090321100_dkac352-B77","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s10096-018-3241-7","article-title":"Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation","volume":"37","author":"Rodriguez-Goncer","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022112510090321100_dkac352-B78","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.202002-0355OC","article-title":"Pulmonary aspergillosis in patients with suspected ventilator-associated pneumonia in UK ICUs","volume":"202","author":"Loughlin","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2022112510090321100_dkac352-B79","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022112510090321100_dkac352-B80","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med"},{"key":"2022112510090321100_dkac352-B81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12879-021-05774-9","article-title":"Antifungal stewardship in a tertiary care paediatric hospital: the PROAFUNGI study","volume":"21","author":"Mendoza-Palomar","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2022112510090321100_dkac352-B82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/INF.0000000000002983","article-title":"Global divergence of antifungal prescribing patterns: data from the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children Surveys","volume":"40","author":"Ferreras-Antolin","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2022112510090321100_dkac352-B83","doi-asserted-by":"crossref","first-page":"e01477-16","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112510090321100_dkac352-B84","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.01427-16","article-title":"Population pharmacokinetics of liposomal amphotericin B in immunocompromised children","volume":"60","author":"Lestner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112510090321100_dkac352-B85","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112510090321100_dkac352-B86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022112510090321100_dkac352-B87","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10156-011-0357-4","article-title":"Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children","volume":"18","author":"Sunakawa","year":"2012","journal-title":"J Infect Chemother"},{"issue":"Suppl 7","key":"2022112510090321100_dkac352-B88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022112510090321100_dkac352-B89","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022112510090321100_dkac352-B90","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"2022112510090321100_dkac352-B91","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children","volume":"158","author":"Caselli","year":"2012","journal-title":"Br J Haematol"},{"key":"2022112510090321100_dkac352-B92","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2022112510090321100_dkac352-B93","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"2022112510090321100_dkac352-B94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jiac.2020.10.005","article-title":"A real-world prospective observational study on the efficacy and safety of liposomal amphotericin B in 426 patients with persistent neutropenia and fever","volume":"27","author":"Yoshida","year":"2021","journal-title":"J Infect Chemother"},{"key":"2022112510090321100_dkac352-B95","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2022112510090321100_dkac352-B96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2022112510090321100_dkac352-B97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ejh.12910","article-title":"Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients","volume":"99","author":"Cesaro","year":"2017","journal-title":"Eur J Haematol"},{"key":"2022112510090321100_dkac352-B98","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/myc.12862","article-title":"Invasive mucormycosis in children with cancer: a retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association","volume":"62","author":"Muggeo","year":"2019","journal-title":"Mycoses"},{"key":"2022112510090321100_dkac352-B99","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B \u2013 the past","author":"Br\u00fcggemann","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2022112510090321100_dkac352-B100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1439-0507.2011.02040.x","article-title":"Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy","volume":"54","author":"Ruhnke","year":"2011","journal-title":"Mycoses"},{"key":"2022112510090321100_dkac352-B101","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/Supplement_2\/ii11\/47257579\/dkac352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/Supplement_2\/ii11\/47257579\/dkac352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:35:43Z","timestamp":1701174943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/Supplement_2\/ii11\/6845631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":101,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2022,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac352","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,11,25]]}}}